Johnson & Johnson acquired Intra-Cellular Therapies and is seeking FDA approval for related drugs.

The entities involved

• FDA →
  • The illegal U.S. vape market is estimated to be worth $9 billion, fueled by unauthorized imports from China, while products must meet FDA authorization standards.Sun 20:36
  • VDPHL01 and Veradermics, Incorporated are seeking FDA approval for their lead therapies targeting hair loss.Sun 20:31
• Johnson & Johnson →

  U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer

  • Coca-Cola and Johnson & Johnson announced dividend raises, while SmartAsset continues to assist users with retirement planning.Sun 20:51
  • UK approved Johnson & Johnson's oral psoriasis treatment, and Amundi increased its holdings in J&J shares.Sun 09:51

Related events

• Johnson & Johnson joins the USMN initiative.Thu 14:49
• Pfizer, J&J, BMS, Sanofi, and AbbVie are leading innovation in personalized therapies and are key players in the multiple myeloma treatment market.Jun 7
• Institutional investors boosted their stake in Johnson & Johnson (JNJ) shares, highlighting the company's drug profits and balance sheet in filings with the SEC.Jun 11
• Johnson & Johnson's MedTech segment missed Q3 estimates, while JNJ's P/E ratio was compared against Eli Lilly and Pfizer.Oct 14
• FDA approval expands patient access to therapies for ACCORD.Jul 10